8-K current report · filed Nov 10, 2026

TriSalus Life Sciences, Inc. (TLSI) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1TLSI overview

Short answer

TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.

TriSalus Life Sciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Full operating and financial details contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $12.9M, up 11.3% YoY, signaling continued TriNav adoption despite slower-than-expected salesforce productivity
  • Gross margin expanded to 86.2% from 83.5%, while operating loss narrowed to $7.7M from $9.0M
  • 2026 revenue guidance reset to $46M-$48M, implying 2%-6% growth and a more measured near-term outlook
  • CMS reimbursement materially improves January 2027: C8004 payment rises to approximately $20,910 from $11,794
  • CMS also established approximately $13,800 office-based-lab payment for PEDD, broadening 2027 commercialization potential

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TriSalus Life Sciences, Inc. 8-K filings

Get the next TLSI 8-K as it lands

Follow TLSI for push alerts, or ask the research agent what this filing means.